New Investment Opportunity: PolarisQB

New Investment Opportunity: Polaris^qbQuantum computing-powered drug discovery

Polaris^qb uses quantum computing, AI to reduce key component of new drug discovery from multiyear, multimillion-dollar process to 4 months and under $100K
6 active projects with 3 paying clients and a collaborator: Allosteric Bioscience Inc, PhoreMost Ltd, Auransa, one undisclosed
Successfully designed and synthesized its first molecule, proved the in-vitro activity that Polaris^qb predicted
IP-protected drug pipeline includes Dengue Fever treatment developed and jointly owned with Fujitsu, two more molecules for potential therapies
On track for first revenue of $1M in 2022, projecting $5.6M in 2023
Experienced computational chemistry team, only company using quantum to develop small molecule-based drugs
CLA with $40M cap at 20% discount led by OurCrowd

BOOK A CALL
with your Investor Relations representative

Dear Josb,

Only 12% of new drugs that enter clinical trials earn FDA approval. Including the money wasted on drugs that fail, the average cost of bringing a new drug to market is $2.6B. The crucial first step, drug discovery, takes years and costs millions of dollars.

OurCrowd is reinvesting in Polaris Quantum Biotech (Polaris^qb), a US-based startup that uses quantum computing to reduce the time needed for a critical stage of drug discovery from four years to four months, while reducing the cost of the multimillion-dollar process to less than $100K. The details in this email are based on information received from, and verified solely by, the company.

The Problem
The current lengthy drug discovery process includes multiple optimization cycles of design, synthesis, and measurements with each cycle adding only incremental improvements when time is of the essence and funding is often limited.

The drug discovery market has experienced accelerated growth since Covid-19 and pharmaceutical companies are finding that more of their processes can be outsourced and expedited.

The Solution
Polaris^qb is the first company to successfully deploy quantum computing in the search for new drugs.

Polaris^qb uses quantum annealing, a quantum computing technique that allows them to scan billions of molecules in one minute.

Polaris^qb's Tachyon drug development platform uses an automated process to search vast chemical libraries, while scaling up to execute multiple parallel projects simultaneously. By using proprietary software for quantum systems that designs molecular assets faster and with higher quality than anyone else, Polaris^qb is able to find novel molecules to develop new drug leads in a fraction of the time and cost than current drug development processes. The technology also includes internal process flow control and artificial intelligence (AI) / machine learning (ML) built into Tachyon activities and data storage.

Polaris^qb provides drug development services for fees and is also developing its own proprietary portfolio of molecular assets that can be licensed or developed internally.

Traction
Polaris^qb reports substantial progress since OurCrowd's last investment in August 2021:

Four active projects with three paying clients: Allosteric Bioscience Inc, PhoreMost Ltd, and one undisclosed. These projects are pursuing the development of drugs against aging-related diseases and incurable oncologic targets.
Two collaborations with Auransa to develop therapeutics for neglected diseases disproportionately affecting women.
Successfully designed and synthesized its first molecule, proving the in-vitro activity that Polaris^qb predicted.
IP-protected drug pipeline includes a Dengue Fever treatment developed and jointly owned with Fujitsu, plus two more molecules for potential therapies.
On track for first-year revenue of $1M in 2022, projecting $5.6M in 2023.

The Team
Polaris^qb has an experienced computational chemistry team headed by CEO Dr. Shahar Keinan who holds three patents, has over 50 publications, and previously served as CSO for Cloud Pharmaceuticals.

The Round
OurCrowd is leading this CLA with a $40M cap at a 20% discount. Funds will be used to support development of new molecular assets and to scale up the platform.

Meet the CEO
We're hosting a webinar/conference call on Tuesday, June 21st, at 6PM Israel / 11AM New York / 8AM San Francisco for investors to meet CEO Shahar Keinan and learn more about Polaris^qb.

Can't make the webinar? Register and we will send you a recording of the call.

The Polaris^qb Solution
Polaris^qb's Tachyon platform uses D-Wave's quantum annealer to achieve unparalleled performance, scanning billions of molecules in one minute.

The process starts with bioinformatics, selecting a biological target leveraging artificial intelligence and machine learning. A molecular library is used to build a solution space of billions of molecules. Quantum computing is used to find the right molecules.

After the right molecules are found, they are synthesized and measured, and the company files for IP protection to support a sale/licensing of the asset.

Next steps:

Certain information in this email contains "forward-looking information" under applicable securities laws ("forward-looking statements"). These may include, among others, projected performance; expected development of the company's business, projects and partnerships; execution of the company's vision and growth strategy; and the like. Forward-looking statements are not guarantees of future performance and should not be relied on in any way.

Nothing contained in and accompanying this communication shall be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security by OurCrowd, its portfolio companies or any third party. Information regarding OurCrowd's limited partnerships and/or portfolio companies and the investment opportunities on OurCrowd's website is intended and available for accredited investors only (criteria at OurCrowd). OurCrowd urges potential investors to consult with licensed legal professionals and investment advisors for any legal, tax, insurance, or investment advice.OurCrowd operates in Canada through OurCrowd Canada Inc., an exempt market dealer registered in the Provinces of British Columbia, Alberta, Manitoba, Ontario, Quebec and Nova Scotia.